FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to compounds, which possess an inhibiting activity with respect to anti-apoptotic Bcl-2 proteins. The invention also relates to a pharmaceutical composition, containing the said compounds, and to a method of treating urinary bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukaemia, colorectal cancer, oesophageal cancer, hepatocellular cancer, lymphoblast leukosis, follicular lymphoma, lymphoid malignant diseases of a T-cell or B-cell origin, melanoma, myelogenous leukaemia, myeloma, oral cavity cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small-cell lung cancer or spleen cancer.
EFFECT: obtaining the compounds, possessing the inhibiting activity with respect to anti-apoptotic Bcl-2 proteins.
4 cl, 5 tbl, 405 ex
Title | Year | Author | Number |
---|---|---|---|
APOPTOSIS INDUCING AGENTS FOR TREATING MALIGNANT NEW GROWTH, AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2535347C2 |
APOPTOSIS-INDUCING MEANS FOR TREATMENT OF MALIGNANT TUMOUR AND IMMUNE AND AUTOIMMUNE DISEASES | 2015 |
|
RU2628885C2 |
APOPTOSIS-INDUCING AGENTS FOR TREATING MALIGNANT TUMOURS AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2573832C2 |
APOPTOSIS-INDUCING AGENTS FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2014 |
|
RU2662812C2 |
APOPTOSIS-INDUCING PREPARATIONS FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2009 |
|
RU2527450C2 |
BLC-2 SELECTIVE AGENTS CAUSING APOPTOSIS FOR TREATING CANCER AND IMMUNE DISEASES | 2009 |
|
RU2497822C2 |
BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR TREATING CANER AND IMMUNE DISEASES | 2010 |
|
RU2542994C2 |
APOPTOSIS-INDUCING AGENTS FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2535203C2 |
APOPTOSIS INDUCING AGENTS SELECTIVE FOR Bcl-2 FOR CANCER AND IMMUNE DISEASES TREATMENT | 2013 |
|
RU2621052C2 |
SOLID DISPERSIONS PRODUCED BY MELT EXTRUSION AND CONTAINING APOPTOSIS-INDUCING AGENT | 2011 |
|
RU2577859C2 |
Authors
Dates
2015-06-27—Published
2010-11-22—Filed